Effects of Electroconvulsive Therapy (ECT) in Bipolar Depression
|ClinicalTrials.gov Identifier: NCT01557933|
Recruitment Status : Withdrawn (Due to a lack of participants, this study has been closed.)
First Posted : March 20, 2012
Last Update Posted : November 29, 2012
The primary purpose of this study is to use magnetic resonance spectroscopy (MRS) to measure the levels of several brain chemicals including, but not limited to, glutamate, glutamine, and N-acetylaspartate, before and after treatment with ECT. In addition to MRS, the investigators will use several other MRI techniques including structural MRI, resting state functional MRI (fMRI), and diffusion tensor imaging (DTI) to measure how the structure and function of the brain changes with ECT.
The investigators hypothesize that the Gln/Glu ratio is increased in the anterior cingulate cortex (ACC), but not the parieto-occipital cortex (POC), following the first ECT treatment.
|Condition or disease||Intervention/treatment|
|Bipolar Disorder||Other: No interventions will be used|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||A Study of the Acute and Chronic Effects of Electroconvulsive Therapy on Glutamatergic Neurotransmission in Bipolar Depression|
|Study Start Date :||April 2011|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||July 2012|
All study subjects have consented to receive ECT.
Other: No interventions will be used
No interventions will be used
- Gln/Glu ratio following the first ECT treatment [ Time Frame: Participants will undergo an MR scan within 24 hours of their first ECT treatment ]The Gln/Glu ratio is examined in the anterior cingulate cortex (ACC) and the parieto-occipital cortex (POC) following the first ECT treatment.
- The Gln/Glu ratio following the sixth ECT treatment. [ Time Frame: Participants will undergo an MR scan within 24 hours of their sixth ECT treatment, which is approximately two weeks after their first ECT treatment ]The Gln/Glu ratio is examined in both the ACC and POC following the sixth ECT treatment.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01557933
|Principal Investigator:||Brian P Brennan, M.D.||Mclean Hospital|